Novartis copy of Amgen arthritis drug highly similar: FDA staff

A Novartis logo is pictured on its headquarters building in MumbaiNovartis AG’s cheaper version of Amgen Inc’s blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug Administration staff. The review, posted on the FDA’s website on Monday, comes two days ahead of a meeting of outside advisors who will discuss the drug and recommend whether it should be approved. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.


Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us